Beta Thalassemia Epidemiology Forecast

DelveInsight’s ‘Beta Thalassemia – Epidemiology Forecast—2032’ report delivers an in-depth understanding of Beta thalassemia historical and forecasted epidemiology in the United States and EU5 (Germany, Spain, Italy, France, and the United Kingdom).

Geographies Covered

  • The United States
  • EU5 (Germany, France, Italy, Spain, and the United Kingdom)

Study Period: 2019–2032

Beta Thalassemia Disease Understanding

Beta Thalassemia (β-Thalassemia) is a blood disorder characterized by reduced synthesis of the hemoglobin subunit beta (hemoglobin beta chain) that results in microcytic hypochromic anemia, an abnormal peripheral blood smear with nucleated red blood cells, and reduced amounts of hemoglobin A (HbA) on hemoglobin analysis.

Beta Thalassemia Epidemiology

The Beta Thalassemia epidemiology division provides insights about the historical and current patient pool, along with the forecasted trend for every seven major countries. It helps recognize the causes of current and forecasted trends by exploring numerous studies and views of key opinion leaders. This part of the report also provides the diagnosed prevalence, diagnosed Beta thalassemia by patient type, trends, and assumptions.

 

Key Findings

The total prevalent cases of Beta Thalassemia patients are increasing in 6MM during the study period, i.e., 2019–2032.

 

The disease epidemiology covered in the report provides historical as well as forecasted Beta Thalassemia symptoms epidemiology segmented as the Total prevalent cases of Beta Thalassemia minor, the Diagnosed prevalence of Beta thalassemia, and Diagnosed Beta Thalassemia patients by disease type. The report includes the prevalent scenario of Beta Thalassemia symptoms in 6MM covering the United States and EU5 countries (Germany, France, Italy, Spain, and the United Kingdom) from 2019 to 2032.

Country-wise Beta Thalassemia Epidemiology

The epidemiology segment also provides the Beta Thalassemia epidemiology data and findings across the United States and EU5 (Germany, France, Italy, Spain, and the United Kingdom).

  • The prevalent cases of Beta Thalassemia minor associated in 6MM countries were 12,536 in 2020.
  • As per the estimates, the United States has the second-largest prevalent population of Beta Thalassemia
  • Among the EU5 countries, Italy had the highest prevalent cases of Beta Thalassemia, followed by Germany, the UK, and France. On the other hand, Spain had the lowest prevalent cases with 275 cases in 2020.

Scope of the Report

  • The Beta Thalassemia report covers a detailed overview explaining its causes, symptoms, and classification, pathophysiology, molecular genetics, diagnosis, and treatment patterns.
  • The Beta Thalassemia Epidemiology Report and Model provide an overview of Beta Thalassemia’s risk factors and global trends in the six major markets (6MM: US, France, Germany, Italy, Spain, and the UK).
  • The report provides insight into Beta Thalassemia’s historical and forecasted patient pool in six major markets covering the United States andEU5 (Germany, Spain, France, Italy, UK).
  • The report helps to recognize the growth opportunities in the 6MM concerning the patient population.
  • The report assesses the disease risk and burden and highlights the unmet needs of Beta thalassemia.
  • The report provides the segmentation of the Beta Thalassemia epidemiology by Total prevalent cases of Beta Thalassemia minor in 6MM.
  • The report provides the Beta Thalassemia epidemiology segmentation by the Diagnosed prevalence of Beta Thalassemia cases in 6MM.
  • The report provides the Beta Thalassemia epidemiology segmentation by diagnosing Beta Thalassemia patients by disease type cases in 6MM.

Report Highlights

  • 11-year Forecast of Beta Thalassemia epidemiology
  • 6MM Coverage
  • Total prevalent cases of Beta Thalassemia minor
  • Diagnosed Prevalence of Beta Thalassemia cases
  • Diagnosed Beta Thalassemia patients by disease type

KOL Views

We interview KOLs, and SMEs’ opinions through primary research to fill the data gaps and validate our secondary research. The opinion helps understand the total patient population and current treatment pattern. This will support the clients in potential upcoming novel treatment by identifying the overall scenario of the indications.

Key Questions Answered

  • What major factors will drive the change in the patient population in Beta Thalassemia during the forecast period (2019–2032)?
  • What are the key findings of the Beta Thalassemia epidemiology across 6MM, and which country will have the highest number of patients during the forecast period (2019–2032)?
  • What would be the total number of Beta Thalassemia patients across the 6MM during the forecast period (2019–2032)?
  • Among the EU5 countries, which country will have the highest number of patients during the forecast period (2019–2032)?
  • At what CAGR the patient population is expected to grow in 6MM during the forecast period (2019–2032)?
  • What are the disease risk, burden, and unmet needs of Beta Thalassemia?
  • What are the currently available treatments for Beta Thalassemia?

Reasons to buy

The Beta Thalassemia epidemiology report will allow the user to -

  • Develop business strategies by understanding the trends shaping and driving the global Beta Thalassemia market.
  • Quantify patient populations in the global Beta Thalassemia market to improve product design, pricing, and launch plans.
  • Organize sales and marketing efforts by identifying the age groups and sex that present the best opportunities for Beta Thalassemia therapeutics in each market covered.
  • Understand the magnitude of the Beta Thalassemia minor population by its prevalence.
  • Understand the magnitude of the Beta Thalassemia population by its Diagnosed prevalence cases.
  • Understand the magnitude of the Beta Thalassemia population by its Diagnosed patients of Beta Thalassemia by disease type cases.
  • The Beta Thalassemia epidemiology report and model were written and developed by Masters and PhD level epidemiologists.
  • The Beta Thalassemia Epidemiology Model developed by DelveInsight is easy to navigate, interactive with dashboards, and epidemiology based on transparent and consistent methodologies. Moreover, the model supports data presented in the report and showcases disease trends over a 10-year forecast period using reputable sources.

Key Assessments

  • Patient Segmentation
  • Disease Risk and Burden
  • Risk of disease by the segmentation
  • Factors driving growth in a specific patient population

1. Key Insights

2. Report Introduction

3. Beta Thalassemia Market Overview at a Glance

3.1. Market Share (%) Distribution of Beta Thalassemia in 2019

3.2. Market Share (%) Distribution of Beta Thalassemia in 2032

4. Executive Summary of Beta Thalassemia

5. Disease Background and Overview

5.1. Introduction

5.2. Types of Beta Thalassemia

5.3. Molecular Genetics

5.4. Causes and Risk factors

5.5. Etiology

5.6. Pathophysiology

5.7. Major Clinical Manifestations

5.7.1. Other complications associated with Beta thalassemia

5.8. Diagnosis of Beta Thalassemia

5.8.1. Diagnostic Guidelines

5.8.2. New Born Screening for Beta Thalassemia

5.9. Treatment and Management of Beta thalassemia

5.9.1. Treatment Guidelines

6. Epidemiology and Patient Population

6.1. Key Findings

6.2. 6MM Total Prevalent Population of Beta Thalassemia

6.3. Epidemiology of Beta Thalassemia

6.4. The United States

6.4.1. Total Prevalent Cases of Beta Thalassemia Minor in the United States

6.4.2. Diagnosed Prevalence of Beta thalassemia in the United States

6.4.3. Diagnosed Beta thalassemia Patients by Disease Type in the United States

6.5. EU-5

6.5.1. Total Prevalent Cases of Beta Thalassemia Minor in EU-5

6.5.2. Diagnosed Prevalence of Beta thalassemia in EU-5

6.5.3. Diagnosed Beta thalassemia Patients by Disease Type in EU-5

7. Appendix

7.1. Bibliography

7.2. Report Methodology

7.3. DelveInsight Capabilities

7.4. Disclaimer

7.5. About Delvelnsight

List of Table

Table 1: Summary of Beta Thalassemia, Market, Epidemiology, and Key Events (2019–2032)

Table 2: Difference between β Thalassemia major and intermediate based on different parameters

Table 3: Summary of Recommendations for diagnosis of TDBT

Table 4: Current Therapies of Beta thalassemia

Table 5: Summary and Recommendations – Management of Transfusion Dependent Thalassemia

Table 6: Treatment Guidelines for Non-Transfusion Dependent Beta Thalassemia

Table 7: Total Prevalent Population of Beta Thalassemia in 6MM (2019–2032)

Table 8: Total Prevalent Cases of Beta thalassemia Minor in the United States (2019–2032)

Table 9: Diagnosed Prevalence of Beta thalassemia in the United States (2019–2032)

Table 10: Diagnosed Beta thalassemia Patients by Disease Type in the United States (2019–2032)

Table 11: Total Prevalent Cases of Beta thalassemia Minor in EU-5 (2019–2032)

Table 12: Diagnosed Prevalence of Beta thalassemia in EU-5 (2019–2032)

Table 13: Diagnosed Beta thalassemia Patients by Disease Type in EU-5 (2019–2032)

List of Figures

Figure 1: Chromosome 11

Figure 2: Red blood cells: healthy and affected

Figure 3: Classification of Beta Thalassemia by types:

Figure 4: Inheritance pattern of Beta Thalassemia

Figure 5: Pathophysiology of Beta Thalassemia

Figure 6: Clinical and Psychosocial concerns among patients in different age-groups

Figure 7: Possible complications associated with Beta thalassemia

Figure 8: Diagnostic algorithm of Beta Thalassemia

Figure 9: Laboratory workup to facilitate diagnosis of NTDT

Figure 10: Total Prevalent Population of Beta Thalassemia in 6MM (2019–2032)

Figure 11: Total Prevalent Cases of Beta thalassemia Minor in the US (2019–2032)

Figure 12: Diagnosed Prevalence of Beta thalassemia in the United States (2019–2032)

Figure 13: Diagnosed Beta thalassemia Patients by Disease Type in the United States (2019–2032)

Figure 14: Total Prevalent Cases of Beta thalassemia Minor in EU-5 (2019–2032)

Figure 15: Diagnosed Prevalence of Beta thalassemia in EU-5 (2019–2032)

Figure 16: Diagnosed Beta thalassemia Patients by Disease Type in EU-5 (2019–2032)

Forward to Friend

Need A Quote